Work

Investigating Real-World Evidence and Reported Survival Outcomes of CDK4/6 Inhibitors in HR+/HER2− Advanced Breast Cancer

Year: 2025

Type: article

Abstract: PointsThe purpose of this commentary is to review the methodological approaches used in key real-world (RW) studies that compared overall survival with cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in metastatic breast cancer.

Source: Oncology and Therapy

DOI: 10.1007/s40487-025-00394-8

Authors: Sarah Sammons, Denise A. Yardley, Priyanka Sharma, Vijayakrishna K. Gadi, Mark Pegram, Purnima Pathak, Huilin Hu, Gary Sopher, Peter A. Fasching

Institutions: Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, University of Kansas Medical Center, Stanford Medicine, Stanford Cancer Institute, Stanford University, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $7,400

Funder: Novartis Pharmaceuticals Corporation

OpenAlex ID: W4416212365

FWCI: 1.177

Cites: 25

Cited by: 2

Related to: